Physician profile
Peter J Imbornone
NPI 1568531432
$1,011.27
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $752 · 2020: $246 · 2021: $13.97.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $241.21 | 2019-2021 | |
| Arbor Pharmaceuticals, INC. | $114.52 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $92.24 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $83.60 | 2019-2020 | |
| Abbvie INC. | $74.34 | 2019-2020 | |
| Pfizer INC. | $65.19 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $62.05 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $43.13 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $42.49 | 2019-2020 | |
| Novo Nordisk INC | $41.49 | 2019-2020 | |
| Horizon Therapeutics Plc | $29.52 | 2019 | |
| Genzyme Corporation | $29.18 | 2019 | |
| Lilly USA, LLC | $27.94 | 2020 | |
| Novartis Pharmaceuticals Corporation | $25.34 | 2019 | |
| Janssen Biotech, INC. | $14.95 | 2019 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi Pasteur INC. | $12.32 | 2019 | |
| Amarin Pharma, INC. | $11.76 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Imbornone listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.